KoreaBIO to Join BIO USA with 51 Companies Participating

Korea Biotechnology Industry Organization(KoreaBIO) announced on June 16 that it will participate in “BIO International Convention 2026 (BIO USA 2026),” which will be held in San Diego, USA, starting from June 22. The association will provide comprehensive support to help Korean bio companies enter the global market.

This year, KoreaBIO will spearhead the “Korea Pavilion,” which it has organized for 23 consecutive years, along with a range of in-depth programs such as Korea Night, the Korea-U.S. Roundtable, business development (BD) seminars, and local company visits. These initiatives are designed to create global partnering opportunities for domestic companies.

Schedule of Korea Biotechnology Industry Organization(KoreaBIO) programs during BIO USA. Korea Biotechnology Industry Organization(KoreaBIO)

At this year’s BIO USA, an official session dedicated to the Korean bio industry will be introduced for the first time. The fact that Korea is being featured as an independent topic at the world’s largest bio industry event is a symbolic indication of Korea’s elevated status and growing global interest in its bio sector.

Korea’s bio industry will be highlighted as an important partner in the global innovative pharmaceutical ecosystem, with a focus on the current state of the Korean bio ecosystem, its innovation capabilities, achievements in global commercialization, and opportunities for collaboration. On the afternoon of June 23, a panel session titled “Korea Rising: Don’t Be Late to Asia’s Next Innovation Hub” will feature Julie Hwang, Director of External Affairs at KoreaBIO; James Choi, Vice President at Samsung Biologics; Chanwoo Kook, CIO of KB Investment; Jaejun Lee, CEO of Il-Dong Pharmaceutical; Sanghoon Lee, CEO of ABL Bio; and Scott Dwyer, Vice President at Boehringer Ingelheim. The panel will introduce various innovation cases from the Korean bio industry, drawing attention from international stakeholders.

This year, a total of 51 Korean bio companies will participate as exhibitors at the Korea Pavilion. Among them, 26 outstanding bio companies have been selected by KoreaBIO and KOTRA, while another 25 companies—supported by Seoul BioHub, the Gyeonggi Institute of Economic Science and Technology, Chuncheon Bio Industry Foundation, and the Korea Evaluation Institute of Industrial Technology (KEIT)—will collaborate organically.

In particular, for three days from June 22 to 24, the “Open Stage,” a company presentation program within the Korea Pavilion, will be held. A total of 29 companies will introduce their core new drug pipelines, platform technologies, latest research and development (R&D) achievements, and global business strategies, seeking opportunities for joint research and investment with global pharmaceutical companies and investors.

“Korea Night,” the most prominent networking event during BIO USA, will take place on June 23 at the Hilton San Diego Bayfront. This year’s event will be jointly hosted by four organizations: KoreaBIO, the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, KOTRA, and the Korea Health Industry Development Institute.

This content was produced with the assistance of AI translation services.